Core Points - Corewell Health and Quest Diagnostics have entered into a joint venture to enhance laboratory services in Michigan [1][4] - The joint venture, named Diagnostic Lab of Michigan, LLC, will establish a 100,000-square-foot laboratory facility featuring advanced technologies [2] - Quest will manage Corewell Health's 21 hospital labs and provide a range of laboratory management services [3][5] - The equity ownership of the joint venture will be 51% for Quest and 49% for Corewell Health [4] - The joint venture is expected to be completed in the first quarter of 2026, with the new laboratory operational by the first quarter of 2027 [5] Company Overview - Corewell Health is a not-for-profit health system with over 65,000 employees, including more than 12,000 physicians and 15,500 nurses [6] - Quest Diagnostics serves a significant portion of the U.S. population, providing diagnostic insights and laboratory testing services [7][8]

Core Insights - Quest Diagnostics has received Breakthrough Device Designation from the FDA for its Haystack MRD® test, aimed at identifying MRD-positive patients with stage II colorectal cancer post-surgery who may benefit from adjuvant therapy [1][3] - The Haystack MRD test is supported by a growing body of research indicating its effectiveness in detecting residual or recurrent cancer from solid tumors, enhancing both clinical and pharmaceutical applications [2][4] Company Overview - Quest Diagnostics is a leading provider of diagnostic information services, serving one in three adult Americans and half of the physicians and hospitals in the U.S. [6] - The company emphasizes the importance of diagnostic insights derived from laboratory testing to improve health outcomes and empower healthcare decisions [6] Product Details - Haystack MRD is a liquid biopsy test designed to detect low levels of circulating-tumor DNA (ctDNA) in the bloodstream, which can indicate residual, recurrent, or resistant disease in cancer patients [5] - The test has been utilized in multiple clinical trials and is available for clinical use across over 75 top cancer and academic centers [5] Research and Development - The Breakthrough Devices Program aims to expedite the development and approval of medical devices that provide effective treatment or diagnosis for life-threatening conditions, which aligns with the goals of Quest Diagnostics in advancing the Haystack MRD test [3] - A recent survey indicated that 96% of oncologists believe MRD testing can identify cancer recurrence earlier than current methods, highlighting the test's potential impact on clinical practices [4]

Core Viewpoint - Quest Diagnostics has shown a positive performance with an 8.2% increase in shares since the last earnings report, outperforming the S&P 500, raising questions about the sustainability of this trend leading up to the next earnings release [1] Financial Performance - In Q2 2025, Quest Diagnostics reported adjusted earnings per share of $2.62, exceeding the Zacks Consensus Estimate by 1.9% and up 11.5% from the previous year [2] - GAAP earnings were $2.47 per share, reflecting a 21.7% increase year-over-year [3] - Revenues for Q2 rose 15.2% year-over-year to $2.76 billion, surpassing the Zacks Consensus Estimate by 1.5% [4] - Diagnostic Information Services revenues increased by 15.7% year-over-year to $2.70 billion, exceeding projections [4] - Volumes measured by requisitions increased by 16.3% year-over-year, while revenue per requisition decreased by 0.4% [5] Margin Analysis - The cost of services was $1.82 billion, up 14.1% year-over-year, with gross profit at $943 million, up 17.3% [6] - Gross margin improved to 34.2%, an increase of 61 basis points [6] - SG&A expenses rose to $486 million, up 16.8% from the previous year, with an adjusted operating margin of 14.6%, representing a 37 basis points expansion [6] Financial Position - At the end of Q2 2025, cash and cash equivalents were $319 million, up from $188 million at the end of Q1 [7] - Cumulative net cash from operating activities was $858 million, compared to $514 million in the same period last year [7] - The company has a five-year annualized dividend growth rate of 7.31% [7] 2025 Guidance - Quest Diagnostics updated its full-year 2025 revenue outlook to a range of $10.80 billion to $10.92 billion, indicating a year-over-year increase of 9.4% to 10.6% [8] - Adjusted earnings per share guidance was revised to a range of $9.63 to $9.83 [8] Estimate Trends - Estimates for the company have trended downward over the past month, indicating a potential shift in market expectations [10][12] - The stock currently holds a Zacks Rank 3 (Hold), suggesting an expectation of in-line returns in the coming months [12] VGM Scores - Quest Diagnostics has a Growth Score of B, a Momentum Score of F, and a Value Score of B, resulting in an aggregate VGM Score of B [11]

Core Insights - Quest Diagnostics Inc. (DGX) is focusing on advanced diagnostics to enhance patient care and drive growth through strategic acquisitions and cost management [1][2][3] Financial Performance - The stock has increased by 20.6% over the past year, outperforming the industry growth of 0.5% and the S&P 500's rise of 15.9% [2] - Quest Diagnostics has a market capitalization of $20.44 billion and an earnings yield of 5.33%, higher than the industry's 4.81% [2] - The company has consistently surpassed earnings estimates over the last four quarters, with an average surprise of 2.09% [2][3] Growth Drivers - The company is targeting five clinical areas for growth: advanced cardiometabolic, autoimmune, brain health, oncology, and women's and reproductive health [3][4] - In Q2 2025, Quest Diagnostics reported double-digit revenue growth in advanced cardiometabolic and autoimmune testing [8] - The acquisition of PathAI Diagnostics aims to enhance AI and digital pathology adoption for improved cancer diagnosis [6][8] Acquisition Strategy - Quest Diagnostics completed eight acquisitions in 2024, including LifeLabs and Allina Health's lab assets, which expanded its market presence [5][6] - Revenue contributions from acquisitions were 10% in Q2, with LifeLabs contributing approximately 8% [6][8] Operational Efficiency - The company is implementing a cost-savings program called Invigorate, targeting 3% annual savings through automation and AI technologies [9][10] - Employee retention has improved, indicating positive trends in workforce management [9] Debt and Economic Concerns - As of Q2 2025, long-term debt stood at $5.17 billion, with cash and cash equivalents at $319 million, raising concerns about financial stability [11] - The evolving U.S. healthcare system poses risks, including potential changes in government payer reimbursement policies [12] Earnings Estimates - The Zacks Consensus Estimate for 2025 earnings per share has increased by 0.4% to $9.74, with revenue estimates at $10.85 billion, indicating a 9.9% growth from the previous year [13]

Core Viewpoint - The healthcare sector is showing initial signs of recovery after reaching a 30-year high in valuation discount relative to the S&P 500 index [1][2] Group 1: Market Performance - Since reaching a historical high on September 3, 2024, healthcare stocks have been in a "persistent downtrend," underperforming both in absolute terms and relative to the S&P 500 [1] - August is identified as a turning point for the sector, with healthcare stocks beginning to reverse their previous weak performance [1] Group 2: Economic Environment - The recovery is driven by a historically significant valuation gap and an economic backdrop characterized by GDP growth slowing to 1.5% or lower while inflation remains at 3% or higher, which historically favors the healthcare sector [1] - The dual effect of valuation discount and improved sentiment provides strong justification for including healthcare stocks in investment portfolios under the current economic conditions [2] Group 3: Investment Recommendations - Evercore ISI highlights several healthcare stocks with attractive valuations and sentiment, including Cencora (COR.US), BioMarin Pharmaceutical (BMRN.US), Cigna (CI.US), Cardinal Health (CAH.US), Humana (HUM.US), Incyte (INCY.US), LabCorp (LH.US), Pfizer (PFE.US), Quest Diagnostics (DGX.US), Teleflex (TFX.US), Tenet Healthcare (THC.US), Universal Health Services (UHS.US), and Viatris (VTRS.US) [2]

Group 1 - The healthcare sector is showing initial signs of recovery after reaching a 30-year high in valuation discount relative to the S&P 500 index [1][2] - Healthcare stocks have been in a "persistent downtrend" since reaching historical highs on September 3, 2024, missing out on market rebounds [1] - The recovery is driven by a historical valuation gap and a macroeconomic environment characterized by GDP growth slowing to 1.5% or lower while inflation remains at 3% or higher, which historically favors healthcare sector performance [1] Group 2 - The current price-to-earnings ratio of the overall market is 25.5 times, while healthcare stocks still present attractive investment options [2] - The potential recovery of healthcare stocks is described as part of "the fastest bear market rebound in history," indicating a larger bull market may extend until 2026 [2] - Evercore ISI recommends healthcare stocks with both valuation and sentiment appeal, including Cencora, BioMarin Pharmaceutical, Cigna, Cardinal Health, Humana, Incyte, Labcorp, Pfizer, Quest Diagnostics, Teleflex, Tenet Healthcare, Universal Health Services, and Viatris [2]

Company Overview - Quest Diagnostics is a leader in diagnostic information services, providing insights from laboratory testing to improve health outcomes [3] - The company serves one in three adult Americans and half of the physicians and hospitals in the United States, employing over 55,000 individuals [3] Upcoming Event - Jim Davis, Chairman, CEO, and President of Quest Diagnostics, will discuss the company's strategy, performance, and market trends at the Baird 2025 Global Healthcare Conference on September 10, 2025, at 10:50 a.m. Eastern Time [1] - The event will be webcast live on the company's investor relations page, with an archived version available within 24 hours after the event, remaining accessible until October 3, 2025 [2]

Core Insights - Digi Power X Inc. has reported significant financial improvements, including the removal of going concern risk and achieving over $30 million in cash and equivalents, which includes approximately 80 Bitcoin and 715 Ethereum [5][7] - The company is positioned to capitalize on the expanding AI infrastructure market, with plans to deploy its first NVIDIA B200 GPU cluster by Q1 2026 and is in advanced negotiations for AI infrastructure contracts [5][8][12] Financial Performance - Positive Adjusted EBITDA was achieved in Q2 2025, marking a milestone towards sustainable profitability [7] - Colocation revenue for the first six months of 2025 reached $9.57 million, a 163% increase year-over-year [7] - Energy sales revenue grew 127% year-over-year in Q2 2025 to $5.7 million [7] - The company reported a net loss of $12.07 million for the six months ended June 30, 2025, compared to a net income of $0.08 million in the same period of 2024 [15] Strategic Developments - The company is on track to deploy its first B200 GPU cluster in partnership with Super Micro Computers, Inc. by Q1 2026 [7] - Digi Power X is in advanced discussions with multiple AI customers to secure long-term infrastructure contracts, which are expected to enhance revenue growth [7][12] - The company plans to expand its operational capacity from approximately 100MW to 200MW and beyond, leveraging its existing asset portfolio and targeted acquisitions [8] Capital and Liquidity - The company raised $12.9 million in Q2 2025 through a private placement and warrant exercises [7] - As of now, Digi Power X holds over $30 million in cash, Bitcoin, Ethereum, and cash equivalents, marking its strongest liquidity position in history [7] - Subsequent to the quarter-end, an additional $1.83 million was raised through warrant exercises [7] Market Outlook - The company anticipates continued strength in colocation and AI infrastructure deployments in the second half of 2025, driven by rising demand from enterprise AI, fintech, and data-intensive sectors [8][12] - Strong partnerships and enhanced liquidity position the company to pursue larger-scale projects, including planned expansions in Alabama and North Carolina [8]

Group 1: Acquisition and Services - Quest Diagnostics has completed the acquisition of select clinical testing assets from Fresenius Medical Care's Spectra Laboratories, enhancing its ability to provide dialysis-related clinical testing to independent dialysis clinics [1] - Quest will also begin providing comprehensive dialysis-related laboratory services for Fresenius-operated dialysis centers, which serve approximately 200,000 patients annually, with the transition expected to be completed by early 2026 [2] Group 2: Operational Benefits - The arrangement allows dialysis clinics to benefit from Quest's clinical leadership and diagnostic innovation in chronic kidney disease services, with multiple Quest laboratories providing testing to nearby clinics, thus reducing transportation time and speeding up results reporting [3] - Quest aims to optimize its return on capital by performing testing during lower-volume daytime hours [3] Group 3: Industry Context - Chronic kidney disease affects about 35.5 million people, or 14% of the U.S. population, making it one of the most prevalent chronic diseases in the U.S. [4] - More than 800,000 people in the U.S. receive dialysis, which requires periodic lab testing to manage the disease and testing water for contaminants [4]

As filed with the United States Securities and Exchange Commission on July 30, 2025 Registration No. 333-_______ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MAINZ BIOMED N.V. (Exact name of registrant as specified in its charter) | | | (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) Mainz Biomed N.V. Rober ...